EGFR and head and neck squamous cell carcinoma: NIR-PIT, using the anti-epidermal growth factor receptor (EGFR) antibody cetuximab conjugated with IR700 (cetuximab sarotalocan sodium, Akalux®: Rakuten Medical Inc., San Diego, CA, USA), was approved for clinical use in patients with unresectable locally advanced or recurrent head and neck squamous cell cancer (HNSCC) in Japan [5,6].